INTRODUCTION {#S1}
============

Merkel cell carcinoma (MCC) is a neuroendocrine skin cancer with a prognosis poorer than that of melanoma. In 2008, a polyomavirus (Merkel cell polyomavirus, MCPyV) was reported to be a likely causative agent for the majority of MCCs([@R6]); this has subsequently been well established by multiple international groups([@R3]; [@R7]; [@R8]). Most MCC tumors depend on persistent expression of viral T-antigen oncoproteins,([@R11]; [@R23];[@R24]) that are targets for the cellular([@R12]) and humoral immune system([@R19]).

It has been well established that immune suppression is associated with increased risk of developing MCC. Indeed, immune suppressed persons make up approximately 10% of the MCC patient population ([@R9]), and it is this link that led to the search for, and eventual discovery of, Merkel cell polyomavirus([@R2]). Multiple forms of systemic immune suppression have been linked with an increased incidence of MCC, including chronic lymphocytic leukemia (CLL) and other hematologic malignancies([@R4]; [@R9]), HIV/AIDS (particularly prior to the widespread adoption of effective antiretrovirals)([@R5]), solid organ transplant([@R21]), and autoimmune disease (with associated treatment regimens)([@R10]).

Conversely, and consistent with a role for anti-viral immune responses in protecting against MCC progression, CD8+ and CD3+ intratumoral lymphocyte responses have been found to be associated with improved MCC outcomes([@R20]; [@R25]). In both of these studies, patients with robust lymphocyte infiltration into the tumor make up a minority of patients but exhibit outstanding MCC-specific survival.

One form of systemic immune suppression, CLL, has recently been associated with reduced MCC survival in a national cancer registry([@R4]). However, to our knowledge, the effect of chronic immune suppression more broadly on MCC outcomes has not been examined. We hypothesized that systemic immune suppression would be associated with worsened MCC-specific survival in a stage-independent manner.

RESULTS {#S2}
=======

Frequency and distribution of systemic immune suppression amongst MCC patients {#S3}
------------------------------------------------------------------------------

Amongst 471 persons with Merkel cell carcinoma from the United States, a total of 41 (8.7%) had clinically recognized systemic immune suppression. Immune suppressed patients were similar to those without immune suppression in terms of age at diagnosis and stage of disease at presentation ([Table 1](#T1){ref-type="table"}), but differed in terms of gender distribution with immune suppressed persons more likely to be male (80% vs. 59%; p \< 0.01). Multiple forms of systemic immune suppression were represented including CLL (n=16; 3% of MCC patient cohort), other hematologic malignancies (n=5; 1%), HIV/AIDS (n=5; 1%), and long-term immunosuppressive medication regimens used for autoimmune disease (n=3; 1%) or solid organ transplant (n=12; 3%).

Persons with systemic immune suppression and MCC have diminished overall survival {#S4}
---------------------------------------------------------------------------------

A combined 1427 years of follow-up was available for the 471 patients with MCC (median 2.1 years). Persons with MCC and systemic immune suppression had worsened overall survival as compared to persons with MCC and no systemic immune suppression (hazard ratio 2.1; p \< 0.01). 3 year overall survival was 33% in the immune suppressed group and 59% in the comparison group.

Persons with systemic immune suppression have worsened Merkel cell carcinoma specific survival {#S5}
----------------------------------------------------------------------------------------------

We hypothesized that persons with systemic immune suppression would have worsened Merkel cell carcinoma--specific survival as compared to persons without systemic immune suppression due to failed immune surveillance of the cancer. We also reasoned that the groups would very likely have different rates of non-MCC death. Therefore, in order to account for possible differences in the death rate from other causes between the two groups, we performed competing risk regression analysis where only deaths from MCC were considered to be events, and deaths from other causes (including non-MCC deaths related to the immune suppression process) were considered to be competing events.

Immune suppressed persons (n=41) had statistically significantly worsened MCC-specific survival as compared to persons without immune suppression (n=430) (hazard ratio 3.0; 95% confidence interval 1.8--4.8; p \< 0.01; [Table 2](#T2){ref-type="table"}). Furthermore, this difference was clinically appreciable, with immune suppressed patients having a three-year survival proportion that was approximately half that of the non-immune suppressed patients (40% vs. 74%; p \< 0.05 for point comparison; [Figure 1](#F1){ref-type="fig"}).

Our patient population represents a non-overlapping mixture of patients enrolled either as individuals (n=228) or as part of records review in institutional sets(n=243). To ensure that our results were similar between the two categories of patients, we looked at each subgroup independently, and found that in each case immune suppression was a significant predictor of worsened outcome (records based enrollment: hazard ratio 2.5; p = 0.01)(individual enrollment: hazard ratio 4.0; p \< 0.01).

Immune suppression is a stage-independent predictor of diminished MCC-specific survival {#S6}
---------------------------------------------------------------------------------------

We observed significantly reduced Merkel cell carcinoma-specific survival among immune suppressed patients at all stages of presentation ([Figure 1](#F1){ref-type="fig"}). In order to formally test whether immune suppression represents an independent predictor of MCC outcome, we performed multivariate competing risk regression analysis accounting for stage at presentation (local-regional-distant stage), age at diagnosis, and sex in addition to immune suppression ([Table 2](#T2){ref-type="table"}). Immune suppression represented a significant independent predictor of worsened MCC-specific survival (hazard ratio 3.8; 95% CI 2.2--6.4; p \< 0.01).

We initially performed our analysis using local-regional-distant stage in order to minimize the number of variables in the model. However, we repeated this analysis using the current American Joint Committee on Cancer (AJCC) 7^th^ Edition staging ([@R15]) instead in order to determine whether immune suppression adds information to current consensus staging. 395 of the 471 patients had sufficient information to determine AJCC substage at presentation. Again, immune suppression was a significant stage-independent predictor of poorer MCC-specific outcome (hazard ratio 4.2; 95% CI 2.4--7.4; p \< 0.01; [Supplemental Table 1](#SD1){ref-type="supplementary-material"}). We performed a third analysis also including lymphovascular invasion status in the model (data available for 149 patients), results were similar and remained significant (hazard ratio 8.9; 95% CI 3.8--21.2; P \< 0.01).

DISCUSSION {#S7}
==========

Merkel cell carcinoma is an aggressive skin cancer. At least 75% of MCC cases have a viral etiology. It has been well established that multiple forms of immune suppression (including HIV, hematologic malignancies, and immunosuppressive medications) are linked with an increased risk of developing MCC([@R5]; [@R9]; [@R10]; [@R13]; [@R14]; [@R21]; [@R22]; [@R25]). However, the effect of systemic immune suppression on MCC prognosis has not been well studied.

We find that systemic immune suppression is a stage-independent predictor of worsened survival among patients with Merkel cell carcinoma. To account for possible differences in overall health between immune suppressed and non-immune suppressed individuals, we performed competing risk regression analysis specifically considering the cause of death. Notably, three year MCC-specific survival was nearly twice as good in the non-immune suppressed group, suggesting systemic immune suppression is of significant clinical importance.

Persons with systemic immune suppression have been found to be at increased risk of developing other skin cancers, including squamous cell carcinoma (SCC), basal cell carcinoma (BCC), and melanoma. SCC incidence is at least 50-fold increased among solid organ transplant recipients([@R18]) and transplant patients with metastatic disease have a poorer SCC prognosis as compared to immune competent patients([@R16]). Furthermore, melanoma has been associated with poorer outcomes among immunocompromised populations as compared to healthy populations([@R17]), and this melanoma-associated mortality significantly increases the total mortality of the immune suppressed patients([@R1]). Combined with our findings regarding MCC, these data highlight the importance of carefully following the skin of immune suppressed persons and having a low threshold for biopsy of suspicious lesions.

Limitations {#S8}
-----------

Our study had several limitations. Many of the patients were enrolled through referral to tertiary centers thus suggesting a source of ascertainment bias. To mitigate this as much as possible, we limited inclusion to patients who presented within 180 days of diagnosis. Given the variable nature of human disease, we were unable to control for the relative degree of immune suppression between various immune suppressed patients. Finally, although MCC is increasing in incidence it remains an uncommon disease. Although our study size of 471 is large for MCC, we still did not have a sufficient number of immune suppressed patients to determine the relative impact of each of the various forms of immune suppression on survival.

Immune suppression is associated with both increased MCC incidence and worsened MCC outcome. Conversely, strong intratumoral immune responses are associated with improved MCC survival([@R19]; [@R25]). Given these associations and the known viral immune targets in MCC, immune therapy holds significant promise for the future treatment of MCC. At this time, in the treatment of patients with immune suppression and MCC, it would appear prudent to follow these higher-risk patients very closely also consider reducing or modifying iatrogenic immune suppression whenever feasible given the clinical context.

METHODS {#S9}
=======

Patient enrollment {#S10}
------------------

All studies were institutional review board approved (FHCRC IRB\# 6585), performed in accordance with Helsinki principles, and written informed patient consent was obtained. All MCC patients in the FHCRC repository of data and specimens were considered for inclusion and all were enrolled in the United States. Enrollment criteria included (all must be present): a diagnosis of Merkel cell carcinoma confirmed by two pathologists, presence of follow-up information, known stage at diagnosis (local-regional-distant), known age at diagnosis, known sex, and known immune suppression status. Patients in the repository enroll in one of two approaches: either as individuals (through our tertiary referral clinic and the internet) or through records review as part of a patient set from one of several institutions (including a 186 patient cohort from Kaiser Permanente, a large integrated health care delivery system in Northern California). Patients were represented only once. Patients enrolling as individuals after 180 days of diagnosis were eliminated in order to reduce ascertainment bias. A total of 471 unique patients with Merkel cell carcinoma met all criteria (243 from institution cohorts and 228 as individuals); demographics are described in [Table 1](#T1){ref-type="table"}.

Statistical analyses {#S11}
--------------------

Demographic and stage information was compared between immune suppressed and non-immune suppressed persons using Fisher's exact test. Overall survival analyses (considering deaths from any cause to be events) were performed with Cox regression. Disease-specific survival analyses were performed with competing risk regression. For competing risk regression, deaths from Merkel cell carcinoma were considered to be events (n=126), deaths from other causes were considered to be competing events (n=75), deaths from unknown causes were censored on the day of death (n=31), and living patients were censored on the date of last follow-up (n=239). Kaplan-Meier curves were generated in order to visually compare survival between groups. Statistical analyses were performed with Stata version 11.0 software for Macintosh. A p-value of 0.05 was considered to be the cutpoint for statistical significance.
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MCC

:   Merkel cell carcinoma

CLL

:   chronic lymphocytic leukemia
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**Large graph:** Persons with immune suppression (n=41) had significantly worsened Merkel cell carcinoma (MCC) specific survival as compared to those without systemic immune suppression (n=430) on univariate (hazard ratio 3.0; p \< 0.01) and multivariate (hazard ratio 3.8; p \< 0.01) competing risk regression analyses ([Table 2](#T2){ref-type="table"}). Numbers at risk at one, three, five, and seven years indicated below. **Small graphs:** Effects of immune suppression persisted across stage at presentation.](nihms408859f1){#F1}

###### Demographics

Immune suppressed and non-immune suppressed patient groups were similar in terms of stage at diagnosis and patient age but differed in their gender distributions, with immune suppressed patients being more likely to be male. Age quartiles for the 25^th^, 50^th^, 75^th^ percentile were 63 years, 72 years, 79 years for the not immune suppressed group and 58 years, 67 years, 77 years for the immune suppressed group. Comparisons made using Fisher's Exact Test. N=471.

  -----------------------------------------------------------------------------------------------
                           Not immune suppressed\   Immune suppressed\   P-value         
                           (n= 430)                 (n=41)                               
  ------------------------ ------------------------ -------------------- --------- ----- --------
  **STAGE AT DIAGNOSIS**                                                                 

  *Local*                  242                      56%                  23        56%   0.94\
                                                                                         (N.S.)

  *Regional*               147                      34%                  15        37%   

  *Distant*                41                       10%                  3         7%    

  **SEX**                                                                                

  *Female*                 177                      41%                  8         20%   \<0.01

  *Male*                   253                      59%                  33        80%   

  **AGE AT DIAGNOSIS**                                                                   

  \< *65 years*            127                      30%                  17        41%   0.16\
                                                                                         (N.S.)

  \>= *65 years*           303                      70%                  24        59%   
  -----------------------------------------------------------------------------------------------

###### Multivariate Competing Risk Regression Analyses Demonstrate Immune Suppression Is an Independent Predictor of Poor Merkel Cell Carcinoma Specific Survival

Left column: univariate analyses considering each listed variable. Right column: multivariate analysis including all listed variables.

                                          Univariate                            Multivariate                                         
  --------------------------------------- ------------------------------------- -------------- ------------------------------------- ------------
  **EXTENT OF DISEASE AT PRESENTATION**                                                                                              
  *Regional (vs. local)*                  3.4[\*](#TFN1){ref-type="table-fn"}   2.3--5.0       3.5[\*](#TFN1){ref-type="table-fn"}   2.3--5.2
  *Distant (vs. local)*                   6.3[\*](#TFN1){ref-type="table-fn"}   3.6--10.8      7.4[\*](#TFN1){ref-type="table-fn"}   4.2--13.1
  **SEX**                                                                                                                            
  *Female (vs. Male)*                     0.8                                   0.6--1.2       0.9                                   0.6--1.4
  **AGE AT DIAGNOSIS**                                                                                                               
  *Age (per year older)*                  1.00                                  0.98--1.01     1.00                                  0.99--1.02
  **SYSTEMIC IMMUNE SUPPRESSION**                                                                                                    
  *Immunosuppressed (vs. not)*            3.0[\*](#TFN1){ref-type="table-fn"}   1.8--4.8       3.8[\*](#TFN1){ref-type="table-fn"}   2.2--6.4

HR = hazard ratio; \* indicates p \< 0.05. CI = confidence interval. N = 471.
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